Clinical Trials Logo

Adult Acute Myeloid Leukemia clinical trials

View clinical trials related to Adult Acute Myeloid Leukemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06329999 Recruiting - Clinical trials for Myelodysplastic Syndrome

A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

Start date: February 3, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial] is to evaluate mitoxantrone hydrochloride liposomes, subcutaneous injection of cytarabine and G-CSF combined with Venetoclax (CMG+Ven) in adult secondary acute myeloid leukemia and myelodysplastic syndrome with increased primordial cells type 2(MDS-IB2) or elderly acute myeloid leukemia]. The main questions it aims to answer are: - Evaluation of the efficacy - Evaluation of the safety

NCT ID: NCT05429632 Recruiting - Clinical trials for Adult Acute Myeloid Leukemia

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

MO-TRANS
Start date: June 16, 2022
Phase: Phase 3
Study type: Interventional

This is a multi-center, randomized, double-blinded, placebo controlled trial.

NCT ID: NCT05262465 Recruiting - Clinical trials for Adult Acute Myeloid Leukemia

Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Patients enrolled from each center according to confirmed criteria specified in cooperative scheme are recieved induction and consolidation chemotherapy with microtransplantation . Observe the remission rate and 2-year disease-free survival (DFS) and overall survival(OS) rate.

NCT ID: NCT03114670 Recruiting - Clinical trials for Adult Acute Myeloid Leukemia

Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT

Start date: March 25, 2017
Phase: Phase 1
Study type: Interventional

Patients with acute myeloid leukemia(AML) recurred after the allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a dismal prognosis.The investigators developed donor-derived chimeric antigen receptor modified-T cell(CART) to target CD123 for the treatment of AML. The investigators start the Phase I study aimed to treat recurred post-transplantation AML patients using donor-derived CAR-T. The purpose of this study is to assess the safety and effectiveness of anti-CD123 CAR-T cells in patients.